EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an anti-staphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: pre-planned analysis from CAMERA2

Joel Z Y Soo, Tze-Peng Lim, Jayden J Y Ho, Steven Y C Tong, David C Lye, Joshua S Davis, Andrea L H Kwa, Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA2) Study Group

Clinical Microbiology and Infection · 2026

DOI: 10.1016/j.cmi.2026.01.032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Joel Z Y Soo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy, Singapore General Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore,…. Hauptthemen laut MEDLINE: Daptomycin, Vancomycin, Bacteremia, Methicillin-Resistant Staphylococcus aureus. Die Arbeit nennt 22 Literaturangaben. Gefördert von: National Health and Medical Research Council, National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Combination antibiotic therapy may improve treatment success for bacterial infections, but bacterial strain-to-strain variability in synergy and its clinical impact remains unclear. This study evaluated whether positive in vitro interactions (synergy or additivity) between vancomycin or daptomycin and a β-lactam in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections are associated with improved clinical outcomes in the Combination Antibiotic for Methicillin Resistant Staphylococcus aureus (CAMERA2) trial. METHODS: In this post hoc analysis of the multicentre randomized CAMERA2 trial, adults with MRSA bacteraemia were randomly assigned to standard care (vancomycin or daptomycin) or combination therapy with an antistaphylococcal β-lactam. Of 174 combination-therapy patients, 24 were excluded for unavailable isolates or missing outcome data, leaving 150 for analysis. Synergy testing was performed centrally, post hoc, using a microdilution checkerboard assay, stratifying patients into positive interaction (synergy/additivity) and negative interaction (antagonism/indifference) groups. Clinical outcomes-including primary composite end point of 90-day mortality-were compared between groups, using statistical tests and multivariate regression adjusting for confounders. RESULTS: Among 150 patients, 103 were in the positive interaction group and 47 in the negative interaction group. Patient characteristics were similar. The primary composite endpoint of 90-day mortality (34% [16 of 47] vs. 32% [33 of 103], p 0.81) did not differ significantly between groups. Persistent bacteraemia rate at day 2 was higher (32.0% [33 of 103] vs. 19.1% [9 of 47], p 0.10) in the positive interaction group. However, 14-day all-cause mortality was significantly lower in the positive interaction group (2.9% [3 of 103] vs. 12.8% [6 of 47], p 0.03). CONCLUSIONS: Positive interactions between vancomycin or daptomycin and a β-lactam were associated with lower 14-day mortality in MRSA bacteraemia. However, these findings should be interpreted with caution and considered hypothesis generating. Combination therapy may be beneficial when positive interactions are present, not universally effective. Synergy testing may help optimize combination therapy, warranting confirmation in a randomized trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DaptomycinVancomycinBacteremiaMethicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsStaphylococcal Infectionsbeta-LactamsHumansDrug SynergismDrug Therapy, CombinationFemaleMiddle AgedMaleAgedMicrobial Sensitivity TestsTreatment Outcomebeta Lactam AntibioticsAdult

Stichwörter der Autor:innen

BacteraemiaCombination therapyDaptomycinIn vitro synergyMethicillin-resistant Staphylococcus aureus (MRSA)Vancomycin

Substanzen

DaptomycinVancomycinAnti-Bacterial Agentsbeta-Lactamsbeta Lactam Antibiotics

Autor:innen und Institutionen

  • Division of Pharmacy, Singapore General Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Division of Pharmacy, Singapore General Hospital, Singapore, Singapore; SingHealth Duke-NUS Pathology Academic Clinical Programme, Singapore, Singapore; SingHealth Duke-NUS Medicine Academic Clinical Programme, Singapor…
  • Division of Pharmacy, Singapore General Hospital, Singapore, Singapore.
  • Victorian Infectious Disease Service, Royal Melbourne Hospital, and University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, T…
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; National Centre for Infectious Diseases, Singapore, Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapor…
  • Department of Infectious Diseases, John Hunter Hospital, Newcastle, New South Wales, Australia; Menzies School of Health Research, Charles Darwin University, Casuarina, Northern Territory, Australia.

Förderung

  • National Health and Medical Research Council
  • National Medical Research Council

Zitieren

APA

Soo, J. Z. Y., Lim, T. P., Ho, J. J. Y., Tong, S. Y. C., Lye, D. C., Davis, J. S., Kwa, A. L. H., & Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA2) Study Group (2026). Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an anti-staphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: pre-planned analysis from CAMERA2. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2026.01.032

Vancouver

Soo JZY, Lim TP, Ho JJY, Tong SYC, Lye DC, Davis JS, et al. Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an anti-staphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: pre-planned analysis from CAMERA2. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2026.01.032

BibTeX
@article{Soo2026,
  author = {Soo, Joel Z Y and Lim, Tze-Peng and Ho, Jayden J Y and Tong, Steven Y C and Lye, David C and Davis, Joshua S and Kwa, Andrea L H and Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA2) Study Group, Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA2) Study Group},
  title = {Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an anti-staphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: pre-planned analysis from CAMERA2},
  journal = {Clinical Microbiology and Infection},
  year = {2026},
  doi = {10.1016/j.cmi.2026.01.032}
}
Kostenlos starten →